A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)
NCT05001373
Active Not Recruiting
A Phase 1, Randomized, First-in-human, Open-label Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) in HIV-1 Uninfected Adults in Good General Health
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/29/2024
Locations: George Washington University, Washington, District of Columbia +3 locations
Conditions: Hiv
Register for Updates
Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women
NCT04766086
Completed
This phase 2B, placebo-controlled, randomized, observer-blinded trial will evaluate the safety, tolerability, and immunogenicity of the investigational multivalent group B streptococcus vaccine administered concomitantly with Tdap in healthy nonpregnant women 18 through 49 years of age.
Gender:
FEMALE
Ages:
Between 18 years and 49 years
Trial Updated:
04/25/2024
Locations: Alliance for Multispecialty Research, LLC, Newton, Kansas +11 locations
Conditions: Group B Streptococcus Infections
Register for Updates
An Open Label Study of IgG Fc Glycan Composition in Human Immunity
NCT01967238
Terminated
In order to produce better more effective vaccines, it is important to understand the particulars of why individuals have an effective or ineffective immune response to vaccination. We are going to examine specific aspects of the antibody (IgG Fc glycan) made by healthy volunteers who receive different vaccines or who have a viral infection to understand the nature of an effective (or less effective) vaccine response. The results of this research could be used to develop adjuvants to increase/ i... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/23/2024
Locations: The Rockefeller University, New York, New York
Conditions: Healthy
Register for Updates
Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults
NCT04927585
Completed
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of polyvalent env (A,B,C,A/E)/gag (C) DNA and gp120 (A,B,C,A/E) protein vaccines (PDPHV201401) co-administered together with or without adjuvant in repeated doses in healthy, HIV-uninfected adults
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/07/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: HIV Infections
Register for Updates
Flublok or Fluzone With Advax-CpG55.2 or AF03
NCT03945825
Completed
This is a Phase I, randomized, double blinded, clinical trial in up to 240 males and non-pregnant females, 18-45 years of age, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of either the 2018/2019 seasonal Fluzone or Flublok Quadrivalent Influenza Vaccine (QIV) manufactured by Sanofi Pasteur (SP) given without adjuvant or with one of two adjuvant formulations, AF03 or Advax-CpG55.2. Eig... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
03/28/2024
Locations: Emory University School of Medicine, Atlanta, Georgia +7 locations
Conditions: Influenza, Influenza Immunisation
Register for Updates
Vaccination for Recovered Inpatients With COVID-19 (VATICO)
NCT04969250
Completed
In this Phase 4, open-label trial, participants of the ACTIV-3/TICO clinical trial at selected sites who received certain pre-specified blinded investigational agents or placebo as part of that trial, and who have since achieved sustained recovery, and who are still \[TICO assignment\] blinded and who are still within 28 to 90 days after initial TICO randomization, will be randomized in this 2x2 factorial design to one of four groups: (i) immediate versus 12 week deferral of first dose administr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Cedars-Sinai Medical Center (Site 208-002), 8700 Beverly Blvd, Los Angeles, California +29 locations
Conditions: Covid19
Register for Updates
Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer
NCT03848182
Terminated
The investigator is developing an immune therapy against pancreatic cancer. Immune cells, known as "T cells with tumor killing capacity", are involved in this immune therapy. In mice with pancreatic cance there is evidence that one tetanus toxoid (TT) vaccination (that patients receive from childhood) combined with Gemcitabine activates these killer T cells. (Gemcitabine improves T cell responses) These killer T cells are able to destroy tumor cells uploaded with TT protein (such studies are pla... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/25/2024
Locations: Albert Einstein College of Medicine, Bronx, New York
Conditions: Pancreatic Cancer
Register for Updates
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults
NCT05266456
Completed
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 18 to 49 years of age in Phase 1. The Phase 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-24 at 3 dose levels compared to PCV20 in adults aged 50 to 64 years of age in Phase 2.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/25/2024
Locations: CenExel RCA, Hollywood, Florida +12 locations
Conditions: Pneumococcal Vaccines
Register for Updates
A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines
NCT01979406
Completed
The purpose of this study is to evaluate 2 vaccine candidates against anthrax compared to the positive (vaccine) control as studied in normal healthy volunteers.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
03/15/2024
Locations: The Center for Pharmaceutical Research, Kansas City, Kansas +3 locations
Conditions: Anthrax Infection
Register for Updates
Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1
NCT01006798
Completed
The purpose of this study is to compare the safety and immunogenicity over a 9-month period of five different dosages of Ad4-H5-Vtn in volunteers (Vaccinees) who receive three doses of the study vaccine or placebo. In addition, transmission of Ad4-H5-Vtn will be evaluated in all Household Contacts residing with the vaccinated volunteers. Vaccinees also may participate in a substudy in which they receive a booster vaccination with the licensed Influenza Virus Vaccine, H5N1 (Sanofi Pasteur).
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
03/15/2024
Locations: University of Kentucky, Lexington, Kentucky +3 locations
Conditions: Bird Flu, Influenza
Register for Updates
Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults
NCT01491607
Completed
The purpose of this Phase 3 clinical trial is to evaluate the immunogenicity and safety of BioThrax anthrax vaccine in healthy adults following 3 doses of BioThrax. Results of this study will be used to support a post-exposure prophylaxis (PEP) indication for BioThrax. This study will be conducted in the United States (U.S.), in 200 healthy male and female volunteer subjects ages 18 to 65 years. The duration of study participation for each individual subject will be approximately 128 days (4.2... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/14/2024
Locations: Miami Research Associates, Miami, Florida +3 locations
Conditions: Anthrax
Register for Updates
Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults
NCT01263691
Completed
The purpose of this Phase 1 clinical trial is to evaluate the safety, tolerability, and immunogenicity of AV7909 anthrax vaccine in healthy adults. In this study, healthy male and female subjects between 18 and 50 years of age will receive vaccinations via the intramuscular (IM) route at Days 0 and 14. Safety and tolerability will be evaluated via laboratory tests, physical examinations, vital signs, adverse events (AEs), concomitant medications, and local and systemic signs and symptoms of reac... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
03/14/2024
Locations: Miami Research Associates, Miami, Florida +2 locations
Conditions: Bacillus Anthracis (Anthrax) Infection
Register for Updates